PIN-bodies:: A new class of antibody-like proteins with CD4 specificity derived from the protein inhibitor of neuronal nitric oxide synthase

被引:7
作者
Bès, C
Troadec, S
Chentouf, M
Breton, H
Lajoix, AD
Heitz, F
Gross, R
Plückthun, A
Chardès, T
机构
[1] CNRS, UMR 5160, Ctr Pharmacol & Biotchnol Sante, Fac Pharm, F-34093 Montpellier 5, France
[2] CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier, France
[3] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland
关键词
scaffold protein; CD4; protein inhibitor of neuronal nitric oxide synthase; ligand binding; paratope-derived peptide; antibody;
D O I
10.1016/j.bbrc.2006.02.126
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
By inserting the CBI paratope-derived peptide (PDP) from the anti-CD4 13B8.2 antibody binding pocket into each of the three exposed loops of the protein inhibitor of neuronal nitric oxide synthase (PIN); we have combined the anti-CD4 specificity of the selected PDP with the stability, ease of expression/purification, and the known molecular architecture of the phylogenetically well-conserved PIN scaffold protein. Such "PIN-bodies" were able to bind CD4 with a better affinity and specificity than the soluble PDP; additionally, in competitive ELISA experiments, CD4-specific PIN-bodies were more potent inhibitors of the binding of the parental recombinant antibody 13B8.2 to CD4 than the soluble PDP. The efficiency of CD4-specific CBI-inserted PIN-bodies was confirmed in biological assays where these constructs showed higher potencies to block antigen presentation by inhibition of IL-2 secretion and to inhibit the one-way and two-way mixed lymphocyte reactions, compared with soluble anti-CD4 PDP CBI. Insertion of the PDP into the first exposed loop (position 33/34) of PIN appeared to be the most promising scaffold. Taken together, our findings demonstrate that the PIN molecule is a suitable scaffold to expose new peptide loops and generate small artificial ligand-binding products with defined specificities. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:334 / 344
页数:11
相关论文
共 54 条
[1]   NMR-detected order in core residues of denatured bovine pancreatic trypsin inhibitor [J].
Barbar, E ;
Hare, M ;
Makokha, M ;
Barany, G ;
Woodward, C .
BIOCHEMISTRY, 2001, 40 (32) :9734-9742
[2]   Dimerization of the highly conserved light chain shared by dynein and myosin V [J].
Benashski, SE ;
Harrison, A ;
PatelKing, RS ;
King, SM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (33) :20929-20935
[3]   AN ANTIBODY THAT BINDS THE IMMUNOGLOBULIN CDR3-LIKE REGION OF THE CD4 MOLECULE INHIBITS PROVIRUS TRANSCRIPTION IN HIV-INFECTED T-CELLS [J].
BENKIRANE, M ;
CORBEAU, P ;
HOUSSET, V ;
DEVAUX, C .
EMBO JOURNAL, 1993, 12 (13) :4909-4921
[4]   Exploration of requirements for peptidomimetic immune recognition - Antigenic and immunogenic properties of reduced peptide bond pseudopeptide analogues of a histone hexapeptide [J].
Benkirane, N ;
Guichard, G ;
Briand, JP ;
Muller, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (52) :33218-33224
[5]   Mapping the paratope of anti-CD4 recombinant fab 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis [J].
Bès, C ;
Briant-Longuet, L ;
Cerutti, M ;
Heitz, F ;
Troadec, S ;
Pugnière, M ;
Roquet, F ;
Molina, F ;
Casset, F ;
Bresson, D ;
Péraldi-Roux, S ;
Devauchelle, G ;
Devaux, C ;
Granier, C ;
Chardès, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (16) :14265-14273
[6]   Efficient CD4 binding and immunosuppressive properties of the 13B8.2 monoclonal antibody are displayed by its CDR-H1-derived peptide CB1 [J].
Bès, C ;
Briant-Longuet, L ;
Cerruti, M ;
DeBerardinis, P ;
Devauchelle, G ;
Devaux, C ;
Granier, C ;
Chardès, T .
FEBS LETTERS, 2001, 508 (01) :67-74
[7]  
Bes Cedric, 2001, Human Antibodies, V10, P67
[8]   Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold [J].
Beste, G ;
Schmidt, FS ;
Stibora, T ;
Skerra, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) :1898-1903
[9]   Engineering novel binding proteins from nonimmunoglobulin domains [J].
Binz, HK ;
Amstutz, P ;
Plückthun, A .
NATURE BIOTECHNOLOGY, 2005, 23 (10) :1257-1268
[10]  
Briant L, 2000, Adv Pharmacol, V48, P373